Blindsight
#44 v Robotika a Embodied AINeuralink · 4× · naposledy 30. 6. 2026
2
Momentum
Blindsight is an experimental brain implant by Neuralink designed to restore vision in completely blind individuals with an intact visual cortex. It completely bypasses the eyes and optic nerve by feeding camera signals directly into the visual cortex via an electrode array, where they generate phosphenes (points of light). The device received Breakthrough Device status from the US-FDA in September 2024; human clinical trials have not yet officially begun, with first implants expected in 2026. It is based on the same N1 implant platform as Neuralink's first product "Telepathy," but with reversed signal direction (writing instead of reading).
Vývoj momenta
19.05.17.08.
Vlastnosti
| Compliance/Certification | FDA Breakthrough Device Designation since September 18, 2024; not yet market-approved |
| Deployment Model | Surgically implanted device, deployed via robotic insertion (R1 system); currently only within clinical trials (US, Canada, UK) |
| Use Case Scope | Restoring vision in totally blind individuals (including congenital blindness) with intact visual cortex |
| Integrations | Camera glasses capture image data, smartphone processes signals, wireless transmission to implant |
| Platform | N1 implant platform (same hardware as Telepathy), microelectrode array in visual cortex, wirelessly linked to external camera/glasses |
| Price | No official price; trial participants incur no cost (clinical study) |
| Release Date | Not yet released; first human implants announced for 2026, FDA approval pending |